These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 25419117)

  • 1. The role of health technology assessment bodies in shaping drug development.
    Ciani O; Jommi C
    Drug Des Devel Ther; 2014; 8():2273-81. PubMed ID: 25419117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early dialogue with health technology assessment bodies: a European perspective.
    Cuche M; Beckerman R; Chowdhury CA; van Weelden MA
    Int J Technol Assess Health Care; 2014 Dec; 30(6):571-8. PubMed ID: 25816822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
    Oortwijn W; Mathijssen J; Banta D
    Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value added medicines: what value repurposed medicines might bring to society?
    Toumi M; Rémuzat C
    J Mark Access Health Policy; 2017; 5(1):1264717. PubMed ID: 28265347
    [No Abstract]   [Full Text] [Related]  

  • 6. Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study.
    Wang T; McAuslane N; Liberti L; Gardarsdottir H; Goettsch W; Leufkens H
    Front Pharmacol; 2020; 11():594549. PubMed ID: 33390978
    [No Abstract]   [Full Text] [Related]  

  • 7. Improving Interactions Between Health Technology Assessment Bodies and Regulatory Agencies: A Systematic Review and Cross-Sectional Survey on Processes, Progress, Outcomes, and Challenges.
    Ofori-Asenso R; Hallgreen CE; De Bruin ML
    Front Med (Lausanne); 2020; 7():582634. PubMed ID: 33178721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timely, consistent, transparent assessment of market access evidence: implementing tools based on the HTA Core Model® in a pharmaceutical company.
    Ducournau P; Irl C; Tatt I; McCarvil M; Gyldmark M
    Int J Technol Assess Health Care; 2019 Jan; 35(1):10-16. PubMed ID: 30789111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IS THE EUNETHTA HTA CORE MODEL® FIT FOR PURPOSE? EVALUATION FROM AN INDUSTRY PERSPECTIVE.
    Gyldmark M; Lampe K; Ruof J; Pöhlmann J; Hebborn A; Kristensen FB
    Int J Technol Assess Health Care; 2018 Jan; 34(5):458-463. PubMed ID: 30334508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of archetypes for non-ranking classification and comparison of European National Health Technology Assessment systems.
    Allen N; Pichler F; Wang T; Patel S; Salek S
    Health Policy; 2013 Dec; 113(3):305-12. PubMed ID: 24176288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions.
    Wang T; McAuslane N; Liberti L; Leufkens H; Hövels A
    Value Health; 2018 Jun; 21(6):707-714. PubMed ID: 29909876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New trends and challenges in the European regulation of innovative medicines.
    Enzmann H
    Regul Toxicol Pharmacol; 2016 Oct; 80():314-20. PubMed ID: 27237379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early scientific advice obtained simultaneously from regulators and payers: findings from a pilot study in Australia.
    Wonder M; Backhouse ME; Hornby E
    Value Health; 2013; 16(6):1067-73. PubMed ID: 24041357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health technology assessment development in China.
    Chen Y; Banta D; Tang Z
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():202-9. PubMed ID: 19575825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation in Health Technology Assessment and Reimbursement Processes in Europe.
    Akehurst RL; Abadie E; Renaudin N; Sarkozy F
    Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health technology assessment of medical devices: a survey of non-European union agencies.
    Ciani O; Wilcher B; Blankart CR; Hatz M; Rupel VP; Erker RS; Varabyova Y; Taylor RS
    Int J Technol Assess Health Care; 2015 Jan; 31(3):154-65. PubMed ID: 26044729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managed Entry Agreements: Policy Analysis From the European Perspective.
    Dabbous M; Chachoua L; Caban A; Toumi M
    Value Health; 2020 Apr; 23(4):425-433. PubMed ID: 32327159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Quality of health care, accreditation, and health technology assessment in Croatia: role of agency for quality and accreditation in health].
    Mittermayer R; Huić M; Mestrović J
    Acta Med Croatica; 2010 Dec; 64(5):425-34. PubMed ID: 21692267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness research: the view from a pharmaceutical company.
    Berger ML; Grainger D
    Pharmacoeconomics; 2010; 28(10):915-22. PubMed ID: 20831299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Development of the Romanian Scorecard HTA System.
    Radu CP; Chiriac ND; Pravat AM
    Value Health Reg Issues; 2016 Sep; 10():41-47. PubMed ID: 27881276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.